JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

While plenty of studies have been done looking at how blood cells function within bone marrow, new research looks deeper at other cells, and resulted in the collaborators creating a Bone Marrow Atlas.

The recent DUO trial, a global Phase III study, compared the efficacy and safety of duvelisib, an oral PI3K inhibitor, with ofatumumab, an anti-CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously undergone at least one therapy.

Christel Nielsen, associate professor at Lund University, gathered a team of researchers to find the relationship between tattoo ink exposure and malignant lymphoma and lymphoma subtype risk.

A new study in JAMA Network Open suggests that disparities in outcomes between Black and White children with acute myeloid leukemia may be due to differences in pharmacogenomics, which is how genes affect drug responses.

The study found that the average annual costs for individuals with Chronic lymphocytic leukemia (CLL) were significantly higher compared to a matched non-CLL cohort.

Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.